ES2749098T3 - Anticuerpos ANTI-B7-H1 y ANTI-CTLA-4 para tratar el cáncer de pulmón no microcítico - Google Patents

Anticuerpos ANTI-B7-H1 y ANTI-CTLA-4 para tratar el cáncer de pulmón no microcítico Download PDF

Info

Publication number
ES2749098T3
ES2749098T3 ES15722195T ES15722195T ES2749098T3 ES 2749098 T3 ES2749098 T3 ES 2749098T3 ES 15722195 T ES15722195 T ES 15722195T ES 15722195 T ES15722195 T ES 15722195T ES 2749098 T3 ES2749098 T3 ES 2749098T3
Authority
ES
Spain
Prior art keywords
medi4736
tremelimumab
antigen
binding fragment
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15722195T
Other languages
English (en)
Spanish (es)
Inventor
Rajesh Narwal
Paul Robbins
Joyson Karakunnel
Mohammed M Dar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Application granted granted Critical
Publication of ES2749098T3 publication Critical patent/ES2749098T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES15722195T 2014-05-13 2015-05-12 Anticuerpos ANTI-B7-H1 y ANTI-CTLA-4 para tratar el cáncer de pulmón no microcítico Active ES2749098T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461992658P 2014-05-13 2014-05-13
US201562105992P 2015-01-21 2015-01-21
US201562114336P 2015-02-10 2015-02-10
PCT/EP2015/060523 WO2015173267A1 (fr) 2014-05-13 2015-05-12 Anticorps anti-b7-h1 et anti-ctla -4 pour le traitement du cancer du poumon non à petites cellules

Publications (1)

Publication Number Publication Date
ES2749098T3 true ES2749098T3 (es) 2020-03-19

Family

ID=53175516

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15722195T Active ES2749098T3 (es) 2014-05-13 2015-05-12 Anticuerpos ANTI-B7-H1 y ANTI-CTLA-4 para tratar el cáncer de pulmón no microcítico

Country Status (27)

Country Link
US (3) US10232040B2 (fr)
EP (2) EP3603748A1 (fr)
JP (4) JP6648038B2 (fr)
KR (4) KR20230165876A (fr)
CN (2) CN113230398B (fr)
AU (4) AU2015260962B2 (fr)
BR (1) BR122023025321A2 (fr)
CA (1) CA2947471A1 (fr)
CY (1) CY1122642T1 (fr)
DK (1) DK3142751T3 (fr)
ES (1) ES2749098T3 (fr)
GB (1) GB2531094A (fr)
HR (1) HRP20191449T1 (fr)
HU (1) HUE045965T2 (fr)
IL (2) IL248528B (fr)
LT (1) LT3142751T (fr)
ME (1) ME03493B (fr)
MX (1) MX373019B (fr)
PL (1) PL3142751T3 (fr)
PT (1) PT3142751T (fr)
RS (1) RS59134B1 (fr)
RU (1) RU2702332C2 (fr)
SG (2) SG10201810108PA (fr)
SI (1) SI3142751T1 (fr)
SM (1) SMT201900544T1 (fr)
TW (3) TWI707692B (fr)
WO (1) WO2015173267A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015036499A1 (fr) 2013-09-11 2015-03-19 Medimmune Limited Anticorps anti-b7-h1 destinés au traitement de tumeurs
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
PL3142751T3 (pl) * 2014-05-13 2019-12-31 Medimmune Limited Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca
WO2016030455A1 (fr) * 2014-08-28 2016-03-03 Medimmune Limited Anticorps anti-b7-h1 et anti-ctla -4 pour le traitement du cancer du poumon non à petites cellules
GB2535256A (en) * 2014-08-28 2016-08-17 Medimmune Ltd Combination therapy for PD-L1 negative tumors
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
WO2017165742A1 (fr) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Procédés de traitement d'événements indésirables liés à l'immunité gastro-intestinale dans des polythérapies anti-ctla4 et anti-pd-1
JP7069032B2 (ja) 2016-03-24 2022-05-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド がん免疫治療における胃腸の免疫関連有害事象の治療方法
WO2017189433A1 (fr) 2016-04-25 2017-11-02 Medimmune, Llc Compositions comprenant une co-formulation d'anticorps anti-pd-l1 et anti-ctla-4
US10934595B2 (en) * 2016-05-17 2021-03-02 Genecentric Therapeutics, Inc. Methods for subtyping of lung adenocarcinoma
CA3024744A1 (fr) 2016-05-17 2017-11-23 Genecentric Therapeutics, Inc. Procedes de sous-typage du carcinome epidermoide bronchique
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018029474A2 (fr) 2016-08-09 2018-02-15 Kymab Limited Anticorps anti-icos
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
KR20230011473A (ko) 2016-09-06 2023-01-20 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Ｐｄ－ｌ１ 발현 암의 치료 방법
EP3534947A1 (fr) 2016-11-03 2019-09-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
WO2018089780A1 (fr) * 2016-11-11 2018-05-17 Medimmune, Llc Anticorps anti-pd-l1 et anti-ctla-4 pour le traitement du cancer du poumon non à petites cellules
WO2018098352A2 (fr) 2016-11-22 2018-05-31 Jun Oishi Ciblage d'expression du point de contrôle immunitaire induit par kras
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
KR20230145547A (ko) * 2017-02-16 2023-10-17 메디뮨 엘엘씨 방광암의 항-pd-l1 항체 치료
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
EP3728314A1 (fr) 2017-12-19 2020-10-28 Kymab Limited Anticorps bispécifique pour icos et pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
AU2018412532B2 (en) * 2018-03-08 2025-05-08 Astrazeneca Ab Compositions and methods for treating late stage lung cancer
WO2021024020A1 (fr) 2019-08-06 2021-02-11 Astellas Pharma Inc. Polythérapie impliquant des anticorps dirigés contre la claudine 18.2 et inhibiteurs de point de contrôle immunitaire pour le traitement du cancer
JP7487558B2 (ja) 2020-05-25 2024-05-21 船井電機株式会社 面光源装置および表示装置
KR20230035576A (ko) 2020-07-07 2023-03-14 비온테크 에스이 Hpv 양성 암 치료용 rna
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (fr) 2020-12-21 2022-06-30 BioNTech SE Arn thérapeutique pour le traitement du cancer
WO2022135666A1 (fr) 2020-12-21 2022-06-30 BioNTech SE Programme de traitement faisant intervenir des protéines cytokines
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
TW202313682A (zh) 2021-05-18 2023-04-01 英商凱麥博有限公司 抗icos抗體之用途
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
CA3225254A1 (fr) 2021-07-13 2023-01-19 BioNTech SE Agents de liaison multispecifiques contre cd40 et cd137 en polytherapie du cancer
WO2023051926A1 (fr) 2021-09-30 2023-04-06 BioNTech SE Traitement impliquant un arn non immunogène pour vaccination antigénique et antagonistes liant l'axe pd-1
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
JP2024540152A (ja) * 2021-10-29 2024-10-31 オンコシーフォー、インク． 抗ｃｔｌａ－４抗体投与レジメン
WO2023083439A1 (fr) 2021-11-09 2023-05-19 BioNTech SE Agoniste de tlr7 et combinaisons pour le traitement du cancer
WO2023222854A1 (fr) 2022-05-18 2023-11-23 Kymab Limited Utilisations d'anticorps anti-icos
CN120302979A (zh) 2022-12-01 2025-07-11 生物技术公司 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗
JP2026501506A (ja) 2022-12-14 2026-01-16 アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体
WO2025056180A1 (fr) 2023-09-15 2025-03-20 BioNTech SE Procédés de traitement faisant appel à des agents se liant à epcam et cd137 en combinaison avec des antagonistes de liaison à l'axe pd-1
WO2026033885A1 (fr) 2024-08-08 2026-02-12 Astellas Pharma Inc. Polythérapie faisant intervenir des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et agents stabilisant ou augmentant l'expression de cldn18.2
WO2025120867A1 (fr) 2023-12-08 2025-06-12 Astellas Pharma Inc. Polythérapie impliquant des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et anticorps anti-vegfr2
WO2025120866A1 (fr) 2023-12-08 2025-06-12 Astellas Pharma Inc. Polythérapie impliquant des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et agents stabilisant ou augmentant l'expression de cldn18.2
TW202541837A (zh) 2023-12-08 2025-11-01 日商安斯泰來製藥公司 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7158164B2 (en) 2003-08-29 2007-01-02 Fuji Photo Film Co., Ltd. Thermal development method and apparatus
AU2011203119C1 (en) 2005-05-09 2018-06-14 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
PT1907424E (pt) * 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
WO2007113648A2 (fr) * 2006-04-05 2007-10-11 Pfizer Products Inc. Polythérapie à base d'un anticorps anti-ctla4
WO2008100562A2 (fr) 2007-02-14 2008-08-21 Medical College Of Georgia Research Institute, Inc. Indole-amine 2,3-dioxygénase, voies pd-1/pd-l et voies ctla4 dans l'activation des lymphocytes t régulateurs
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
CN102000947B (zh) * 2010-10-14 2012-06-06 沈阳飞机工业（集团）有限公司 两半轴瓦的铣切加工方法
BR112013011176A2 (pt) 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
CN101975831B (zh) * 2010-11-25 2012-09-05 中国检验检疫科学研究院 高效液相色谱法测定化妆品中苯酚磺酸锌的方法
CN102836441B (zh) 2011-06-24 2019-06-11 台北荣民总医院 于感染性与恶性疾病的治疗中提升免疫反应的方法
WO2013169388A1 (fr) * 2012-05-08 2013-11-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Biomarqueurs prédictifs dans le cadre d'une thérapie basée sur le blocage du ctla-4 et d'une thérapie basée sur le blocage de la pd-1
US9846162B2 (en) * 2012-05-14 2017-12-19 Yale University Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer
HK1203971A1 (en) * 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
CA2889182A1 (fr) * 2012-10-26 2014-05-01 The University Of Chicago Combinaison synergique d'inhibiteurs immunologiques pour le traitement du cancer
WO2015012904A2 (fr) * 2012-12-13 2015-01-29 Immunomedics, Inc. Immunoconjugués anticorps-sn-38 avec un lieur cl2a
CA2902433A1 (fr) * 2013-03-01 2014-09-04 Astex Pharmaceuticals, Inc. Combinaisons de medicaments
PL3142751T3 (pl) * 2014-05-13 2019-12-31 Medimmune Limited Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca
WO2016030455A1 (fr) * 2014-08-28 2016-03-03 Medimmune Limited Anticorps anti-b7-h1 et anti-ctla -4 pour le traitement du cancer du poumon non à petites cellules
GB2537445A (en) * 2014-11-10 2016-10-19 Medimmune Ltd Binding molecules specific for CD73 and uses thereof
KR20250004095A (ko) * 2015-04-17 2025-01-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
WO2017189433A1 (fr) * 2016-04-25 2017-11-02 Medimmune, Llc Compositions comprenant une co-formulation d'anticorps anti-pd-l1 et anti-ctla-4
KR20230145547A (ko) * 2017-02-16 2023-10-17 메디뮨 엘엘씨 방광암의 항-pd-l1 항체 치료
US12042527B2 (en) * 2019-01-08 2024-07-23 Modernatx, Inc. Use of mRNAs encoding OX40L, IL-23 and IL-36gamma in combination with immune checkpoint blockade for treating particular cancers

Also Published As

Publication number Publication date
KR20230165876A (ko) 2023-12-05
RU2702332C2 (ru) 2019-10-08
AU2015260962B2 (en) 2020-06-11
KR20210149870A (ko) 2021-12-09
RS59134B1 (sr) 2019-09-30
HRP20191449T1 (hr) 2019-11-15
BR122023025321A2 (pt) 2024-02-20
TWI780994B (zh) 2022-10-11
PT3142751T (pt) 2019-10-25
CN113230398A (zh) 2021-08-10
CN106456756A (zh) 2017-02-22
KR20170003575A (ko) 2017-01-09
SG10201810108PA (en) 2018-12-28
IL276481B (en) 2022-06-01
US20190240324A1 (en) 2019-08-08
RU2016148645A (ru) 2018-06-19
AU2023204286B2 (en) 2025-02-06
BR112016026197A2 (pt) 2018-02-20
GB2531094A (en) 2016-04-13
KR102333658B1 (ko) 2021-12-01
EP3142751B1 (fr) 2019-08-07
AU2020230309A1 (en) 2020-10-01
CN113230398B (zh) 2025-01-03
US20230115328A1 (en) 2023-04-13
JP2017520520A (ja) 2017-07-27
GB201508097D0 (en) 2015-06-24
DK3142751T3 (da) 2019-10-14
JP2021098734A (ja) 2021-07-01
EP3603748A1 (fr) 2020-02-05
PL3142751T3 (pl) 2019-12-31
HUE045965T2 (hu) 2020-01-28
AU2023204286A1 (en) 2023-07-27
CY1122642T1 (el) 2021-03-12
IL248528A0 (en) 2016-12-29
CA2947471A1 (fr) 2015-11-19
US10232040B2 (en) 2019-03-19
JP6648038B2 (ja) 2020-02-14
MX373019B (es) 2020-03-31
TW202123967A (zh) 2021-07-01
JP7519477B2 (ja) 2024-07-19
TWI707692B (zh) 2020-10-21
TW202233239A (zh) 2022-09-01
TW201545759A (zh) 2015-12-16
MX2016014189A (es) 2017-05-04
IL248528B (en) 2020-08-31
AU2020230309B2 (en) 2023-04-20
US20150328311A1 (en) 2015-11-19
ME03493B (fr) 2020-01-20
IL276481A (en) 2020-09-30
RU2019129614A (ru) 2020-07-16
JP2023052607A (ja) 2023-04-11
US11446377B2 (en) 2022-09-20
SI3142751T1 (sl) 2019-09-30
RU2016148645A3 (fr) 2018-12-21
SG11201609285SA (en) 2016-12-29
JP2020090509A (ja) 2020-06-11
AU2025202908A1 (en) 2025-05-15
RU2019129614A3 (fr) 2021-12-27
CN106456756B (zh) 2021-04-23
SMT201900544T1 (it) 2019-11-13
KR20220162844A (ko) 2022-12-08
LT3142751T (lt) 2019-09-25
AU2015260962A1 (en) 2016-11-24
WO2015173267A1 (fr) 2015-11-19
EP3142751A1 (fr) 2017-03-22

Similar Documents

Publication Publication Date Title
ES2749098T3 (es) Anticuerpos ANTI-B7-H1 y ANTI-CTLA-4 para tratar el cáncer de pulmón no microcítico
ES2938321T3 (es) Métodos para tratar el cáncer de piel mediante la administración de un inhibidor de PD-1
ES2825080T3 (es) Anticuerpos humanizados contra CEACAM1
US12565528B2 (en) LAG-3 antagonist therapy for lung cancer
HK40013014A (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
WO2019096233A1 (fr) Utilisation d'une combinaison d'un agent immunothérapeutique, d'un antimétabolite nucléosidique et de platine dans la préparation d'un médicament pour le traitement d'une tumeur
RU2806210C2 (ru) Антитела к b7-h1 и к ctla-4 для лечения немелкоклеточного рака легкого
BR112016026197B1 (pt) Uso de medi4736 e tremelimumab
HK1235023A1 (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
HK1235023B (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer